Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
-42.53%
Shrank
—
—
Shrank
—
1 Year
Score—
Net Growth-42.53%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
2.4
-50.65%
40%
—
-100.00%
Never
—
5 Years
Score2.4
Net Growth-50.65%
Net Trend40%
Net Income Consistency—
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency—
Candel Therapeutics Inc fundamental performance
Between 2021 and 2025, revenue declined from $ 125K to $ 0.00 and net income went from -$ 36M to -$ 38M. Revenue increased in 0% of the years measured; net income in 40%.
Candel Therapeutics Inc currently holds a 5-year HDB Score of 2.4 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 10.68 | — |
1 Year2025-08-12 | $ 6.35 | 68.19% |
5 Years2021-08-12 | $ 8.26 | 29.30% |
All Time2021-07-27 | $ 7.00 | 52.57% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2021-07-27 |
|---|---|---|---|---|
| Price | $ 10.68 | $ 6.35 | $ 8.26 | $ 7.00 |
| Return | — | 68.19% | 29.30% | 52.57% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 0.00 | -$ 54M | $ 194M |
| 2025 | $ 0.00 | -$ 38M | $ 119M |
| 2024 | $ 0.00 | -$ 55M | $ 102M |
| 2023 | $ 31K | -$ 37M | $ 35M |
| 2022 | $ 125K | -$ 18M | $ 70M |
| IPO2021 | $ 125K | -$ 36M | $ 82M |
Explore beyond CADL
You're looking at Candel Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
